At a glance
ClinicalIndex Comparison RecordN/ACompleted· 86,939 enrolled
Drug / intervention
Retrospective study- +3 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events
In Brief
An observational study evaluating Retrospective study- for Parkinson's Disease and Hyperprolactinemia. Completed, enrolled 86,939 participants.
Detailed Summary
To assess the association between cabergoline and other dopamine agonists (DAs), and symptomatic, diagnosed serious cardiopulmonary disorders, including: 1. Cardiac valve regurgitation 2. Diffuse Pleural/pulmonary thickening and pericardial and retroperitoneal fibrosis 3. Heart failure 4. Total, cardiac and respiratory mortality
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease, Hyperprolactinemia
Countries--
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
Primary CompletionDec 2009
First PostedJan 2010
TodayJul 2026
First PostedJan 21, 2010
Enrollment StartJan 1, 2007
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 16.4 years ago
Interventions
Retrospective study-other
Retrospective study-other
Retrospective study-other
Retrospective study-other